ReviewChild's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery2025
Angiocentric glioma: a single center experience and literature review.
Review in Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveAngiocentric glioma (AG) is a very rare neoplasm. Limited literature described this rare lesion and most of them are case reports. Here we report 21 patients with AG and review the literature.
methodsClinical data from the 21 patients who underwent surgical treatment in our institute between 2015 and 2025 were reviewed. We also searched PubMed database between 2005 and 2025 using the keywords "angiocentric glioma" or "angiocentric gliomas" and 74 patients were reviewed.
resultsThe authors' cohort include 12 males and 9 females, with a mean age of 17.9 ± 17.9 years. Gross-total resection (GTR) and non-GTR were achieved in 15 and 6 patients, respectively. After a mean follow-up of 41.7 ± 31.4 months, no patient died and tumor recurrence occurred in 1 patient. In the literature between 2005 and 2025, 74 cases of AG were identified. Among them, 46 cases were males and 28 cases were females with a mean age of 14.7 ± 13.9 years. GTR, non-GTR and biopsy were achieved in 49, 17, 7 cases, respectively. After a mean follow-up of 29.4 ± 31.6 months, 2 patients died, for a mean follow-up of 32.7 ± 36.1 months, 5 patients suffered tumor recurrence. Among all cases that underwent immunohistochemical examination, 98.5% were positive for Glial Fibrillary Acidic Protein (GFAP) and 82.1% were positive for Epithelial Membrane Antigen (EMA). Genetic testing was performed in a total of 6 cases and all of them showed MYB-QKI gene fusion. Progression-Free Survival (PFS) rates at 1, 5, 10 years were 96%, 94% and 77% respectively, and Overall Survival (OS) rates at 1, 5, 10 years were 99%, 99% and 91%.
conclusionAGs are rare tumors with a higher tendency in males and they usually involved the frontal and temporal lobe. In immunohistochemical studies, GFAP and EMA are frequently positive. The MYB-QKI gene fusion is a characteristic feature of this tumor. GTR was regarded as the best treatment. Although most AGs were clinically indolent, a few unusual cases showed aggressive behaviors. A larger cohort with long-term follow-up is necessary to verify our findings.
Indexed as
Identifiers
41288759What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.